Q12 March 2009

Outline the pharmacology of an opioid injected into the spinal intrathecal space.

Pharmaceuticals

- Intrathecal morphine available as 500mcg/mL solution
- Fentanyl available as 50mcg/mL
- Intrathecal opioids must be preservative free
- If in a glass vial, must be drawn up through filter tip needle
- Indications: intra/post-operative analgesia

Pharmacodynamics

- Mechanism of action:
 - o Bind to G-protein-coupled pre and post synaptic receptors in the dorsal horn
 - \circ Causes G-protein-mediated K⁺ channel opening (mu and delta receptors) \rightarrow hyperpolarises cell
 - o Causes G-protein-mediated Ca²⁺ channel receptors (kappa receptors)
 - Causes reduction in intracellular Ca²⁺
 - Leads to decreased release of excitatory transmitters, glutamate and substance P
 - Consequent reduction in nociceptive transmission
- Side effects:
 - o Pruritus
 - o Nausea and vomiting
 - o Urinary retention
 - o Respiratory depression

Pharmacokinetics

	Lipophilic e.g. fentanyl	Hydrophilic e.g. morphine	
Absorption	Highly potentRapid onsetLimited duration of action	Slower onsetLonger duration of action	
Distribution	 Bulk flow in caudal → cephalad direction Fluctuating thoracic pressure changes (or Uptake into posterior radicular artery meta) Rapidly redistributes into other areas, including epidural fat, myelin, white matter High volume of distribution in spinal cord High pKa means less un-ionised molecule is available in receptor sites in grey matter Rapid decreased in CSF concentration Increased epidural and plasma concentrations 	lue to respiration) facilitate this flow	
Metabolism	Opioids metabolised in liver to both act	Removal from CSF facilitated by glycoprotein carrier transport in choroid plexus ive and inactive metabolites	
	 Some extra-hepatic metabolism → kidn 		
Excretion	 In urine and bile Water soluble glucuronides excreted in bile may be metabolised by gut flora back to parent opioid, and reabsorbed (enterohepatic recirculation) 		